高危早期乳腺癌的剂量密集辅助化疗：其在个性化肿瘤学时代的作用。 - Suppr

Suppr

超能文献

Dose-dense adjuvant chemotherapy for high-risk early breast cancer: its role in the era of personalised oncology.

作者信息

Savva Constantinos, Cutress Ramsey, Copson Ellen

机构信息

School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

出版信息

Gland Surg. 2025 Apr 30;14(4):791-796. doi: 10.21037/gs-2025-72. Epub 2025 Apr 25.

DOI:10.21037/gs-2025-72

PMID:40405947

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12093177/

Abstract

摘要

相似文献

Dose-dense adjuvant chemotherapy for high-risk early breast cancer: its role in the era of personalised oncology.高危早期乳腺癌的剂量密集辅助化疗：其在个性化肿瘤学时代的作用。

Gland Surg. 2025 Apr 30;14(4):791-796. doi: 10.21037/gs-2025-72. Epub 2025 Apr 25.

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.量身定制的剂量密集化疗与标准每3周一次辅助化疗对高危早期乳腺癌女性无病生存率的影响：一项随机临床试验

JAMA. 2016 Nov 8;316(18):1888-1896. doi: 10.1001/jama.2016.15865.

Role of dose-dense chemotherapy in high-risk early breast cancer.高危早期乳腺癌中剂量密集化疗的作用。

Curr Opin Oncol. 2019 Nov;31(6):480-485. doi: 10.1097/CCO.0000000000000571.

Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.曲妥珠单抗应用前后 HER2 阳性早期乳腺癌患者的密集化疗：GIM2 试验的探索性分析。

Int J Cancer. 2020 Jul 1;147(1):160-169. doi: 10.1002/ijc.32789. Epub 2019 Dec 4.

Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition.密集型辅助化疗：对 2018 年版日本乳腺癌学会临床实践指南的系统评价和荟萃分析。

Breast Cancer. 2020 May;27(3):334-339. doi: 10.1007/s12282-019-01039-1. Epub 2020 Jan 8.

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.氟尿嘧啶和剂量密集型辅助化疗用于早期乳腺癌患者（GIM2）：一项随机、3 期试验的研究结束时结果。

Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10.

in a patient on dose-dense chemotherapy for early breast cancer.在一名接受密集剂量化疗的早期乳腺癌患者中。

Respirol Case Rep. 2019 Jul 5;7(7):e00459. doi: 10.1002/rcr2.459. eCollection 2019 Oct.

[Feasibility and toxicity of EC-T dose-dense adjuvant chemotherapy: A real world study in Chinese early-stage breast cancer patients with high recurrence risk].EC-T剂量密集辅助化疗的可行性及毒性：中国早期高复发风险乳腺癌患者的一项真实世界研究

Zhonghua Zhong Liu Za Zhi. 2019 May 23;41(5):368-372. doi: 10.3760/cma.j.issn.0253-3766.2019.05.009.

[Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].[紫杉醇和表柔比星辅助剂量密集化疗用于高危乳腺癌的安全性]

Zhonghua Zhong Liu Za Zhi. 2008 Jul;30(7):548-51.

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.绝经前乳腺癌患者的密集化疗：MIG1 和 GIM2 三期研究的汇总分析。

Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10.

本文引用的文献

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.曲妥珠单抗恩美曲妥珠单抗治疗残留HER2阳性乳腺癌的生存情况

N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070.

Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.激素受体阳性乳腺癌的辅助剂量密集化疗

J Clin Oncol. 2025 Apr;43(10):1229-1239. doi: 10.1200/JCO-24-01875. Epub 2025 Jan 2.

Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.乳腺癌剂量密集辅助化疗的获益：3期随机PANTHER试验的亚组分析

Lancet Reg Health Eur. 2024 Dec 3;49:101162. doi: 10.1016/j.lanepe.2024.101162. eCollection 2025 Feb.

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌的总生存期。

N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15.

Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer.三阴性乳腺癌新辅助化疗免疫治疗期间密集剂量与每三周一次阿霉素和环磷酰胺方案的比较

NPJ Breast Cancer. 2024 Aug 14;10(1):73. doi: 10.1038/s41523-024-00676-w.

Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.根据体重指数评估乳腺癌辅助化疗方案的疗效：来自 III 期 GIM2 试验的结果。

ESMO Open. 2024 Aug;9(8):103650. doi: 10.1016/j.esmoop.2024.103650. Epub 2024 Aug 8.

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.个体化剂量密集型与标准辅助化疗治疗高危早期乳腺癌：随机 PANTHER 试验的研究结束时结果。

J Clin Oncol. 2024 Sep 10;42(26):3077-3082. doi: 10.1200/JCO.24.00178. Epub 2024 Jul 17.

Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer.在改良的KEYNOTE522方案中使用密集剂量阿霉素加环磷酰胺治疗三阴性乳腺癌。

NPJ Breast Cancer. 2024 Jun 4;10(1):39. doi: 10.1038/s41523-024-00643-5.

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.辅助阿贝西利联合内分泌治疗激素受体阳性、人表皮生长因子受体 2 阴性、高危早期乳腺癌： monarchE 总生存期中期分析的预先计划结果，包括 5 年疗效结果。

J Clin Oncol. 2024 Mar 20;42(9):987-993. doi: 10.1200/JCO.23.01994. Epub 2024 Jan 9.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.含蒽环类和紫杉类化疗药物治疗早期可手术乳腺癌的患者水平荟萃分析：来自 86 项随机试验的 10 万名女性的研究。

Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验